UniProt ID | LPP_HUMAN | |
---|---|---|
UniProt AC | Q93052 | |
Protein Name | Lipoma-preferred partner | |
Gene Name | LPP | |
Organism | Homo sapiens (Human). | |
Sequence Length | 612 | |
Subcellular Localization | Nucleus. Cytoplasm. Cell junction. Cell membrane. Found in the nucleus, in the cytoplasm and at cell adhesion sites. Shuttles between the cytoplasm and the nucleus. It has been found in sites of cell adhesion such as cell-to-cell contact and focal ad | |
Protein Description | May play a structural role at sites of cell adhesion in maintaining cell shape and motility. In addition to these structural functions, it may also be implicated in signaling events and activation of gene transcription. May be involved in signal transduction from cell adhesion sites to the nucleus allowing successful integration of signals arising from soluble factors and cell-cell adhesion sites. Also suggested to serve as a scaffold protein upon which distinct protein complexes are assembled in the cytoplasm and in the nucleus.. | |
Protein Sequence | MSHPSWLPPKSTGEPLGHVPARMETTHSFGNPSISVSTQQPPKKFAPVVAPKPKYNPYKQPGGEGDFLPPPPPPLDDSSALPSISGNFPPPPPLDEEAFKVQGNPGGKTLEERRSSLDAEIDSLTSILADLECSSPYKPRPPQSSTGSTASPPVSTPVTGHKRMVIPNQPPLTATKKSTLKPQPAPQAGPIPVAPIGTLKPQPQPVPASYTTASTSSRPTFNVQVKSAQPSPHYMAAPSSGQIYGSGPQGYNTQPVPVSGQCPPPSTRGGMDYAYIPPPGLQPEPGYGYAPNQGRYYEGYYAAGPGYGGRNDSDPTYGQQGHPNTWKREPGYTPPGAGNQNPPGMYPVTGPKKTYITDPVSAPCAPPLQPKGGHSGQLGPSSVAPSFRPEDELEHLTKKMLYDMENPPADEYFGRCARCGENVVGEGTGCTAMDQVFHVDCFTCIICNNKLRGQPFYAVEKKAYCEPCYINTLEQCNVCSKPIMERILRATGKAYHPHCFTCVMCHRSLDGIPFTVDAGGLIHCIEDFHKKFAPRCSVCKEPIMPAPGQEETVRIVALDRDFHVHCYRCEDCGGLLSEGDNQGCYPLDGHILCKTCNSARIRVLTAKASTDL | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
5 | Phosphorylation | ---MSHPSWLPPKST ---CCCCCCCCCCCC | 35.50 | 27251275 | |
11 | Phosphorylation | PSWLPPKSTGEPLGH CCCCCCCCCCCCCCC | 47.63 | 25159151 | |
11 | O-linked_Glycosylation | PSWLPPKSTGEPLGH CCCCCCCCCCCCCCC | 47.63 | 30059200 | |
12 | Phosphorylation | SWLPPKSTGEPLGHV CCCCCCCCCCCCCCC | 52.25 | 25159151 | |
12 | O-linked_Glycosylation | SWLPPKSTGEPLGHV CCCCCCCCCCCCCCC | 52.25 | 30059200 | |
25 | Phosphorylation | HVPARMETTHSFGNP CCCCEEEEECCCCCC | 22.07 | 28555341 | |
25 | O-linked_Glycosylation | HVPARMETTHSFGNP CCCCEEEEECCCCCC | 22.07 | 30059200 | |
26 | O-linked_Glycosylation | VPARMETTHSFGNPS CCCEEEEECCCCCCC | 11.38 | 30059200 | |
26 | Phosphorylation | VPARMETTHSFGNPS CCCEEEEECCCCCCC | 11.38 | 28857561 | |
28 | Phosphorylation | ARMETTHSFGNPSIS CEEEEECCCCCCCEE | 32.53 | 28857561 | |
28 | O-linked_Glycosylation | ARMETTHSFGNPSIS CEEEEECCCCCCCEE | 32.53 | 30059200 | |
33 | Phosphorylation | THSFGNPSISVSTQQ ECCCCCCCEEEECCC | 31.34 | 28857561 | |
33 | O-linked_Glycosylation | THSFGNPSISVSTQQ ECCCCCCCEEEECCC | 31.34 | 30059200 | |
35 | Phosphorylation | SFGNPSISVSTQQPP CCCCCCEEEECCCCC | 17.85 | 28857561 | |
35 | O-linked_Glycosylation | SFGNPSISVSTQQPP CCCCCCEEEECCCCC | 17.85 | 30059200 | |
43 | Acetylation | VSTQQPPKKFAPVVA EECCCCCCCCCCCCC | 68.18 | 26051181 | |
44 | Ubiquitination | STQQPPKKFAPVVAP ECCCCCCCCCCCCCC | 53.16 | - | |
44 | Acetylation | STQQPPKKFAPVVAP ECCCCCCCCCCCCCC | 53.16 | 25953088 | |
52 | Malonylation | FAPVVAPKPKYNPYK CCCCCCCCCCCCCCC | 44.39 | 26320211 | |
83 | Phosphorylation | DDSSALPSISGNFPP CCCCCCCCCCCCCCC | 30.18 | 27251275 | |
85 | Phosphorylation | SSALPSISGNFPPPP CCCCCCCCCCCCCCC | 31.83 | 27251275 | |
108 | Acetylation | VQGNPGGKTLEERRS HCCCCCCCCHHHHHH | 56.71 | 27452117 | |
108 | Ubiquitination | VQGNPGGKTLEERRS HCCCCCCCCHHHHHH | 56.71 | - | |
109 | Phosphorylation | QGNPGGKTLEERRSS CCCCCCCCHHHHHHH | 42.55 | 25159151 | |
115 | Phosphorylation | KTLEERRSSLDAEID CCHHHHHHHHHHHHH | 41.28 | 25159151 | |
116 | Phosphorylation | TLEERRSSLDAEIDS CHHHHHHHHHHHHHH | 28.58 | 25159151 | |
123 | Phosphorylation | SLDAEIDSLTSILAD HHHHHHHHHHHHHHH | 38.93 | 28192239 | |
125 | Phosphorylation | DAEIDSLTSILADLE HHHHHHHHHHHHHHC | 20.06 | 20068231 | |
126 | Phosphorylation | AEIDSLTSILADLEC HHHHHHHHHHHHHCC | 22.39 | 20068231 | |
134 | Phosphorylation | ILADLECSSPYKPRP HHHHHCCCCCCCCCC | 25.60 | 23090842 | |
135 | Phosphorylation | LADLECSSPYKPRPP HHHHCCCCCCCCCCC | 43.86 | 18669648 | |
137 | Phosphorylation | DLECSSPYKPRPPQS HHCCCCCCCCCCCCC | 35.26 | 23090842 | |
144 | Phosphorylation | YKPRPPQSSTGSTAS CCCCCCCCCCCCCCC | 35.32 | 26657352 | |
145 | Phosphorylation | KPRPPQSSTGSTASP CCCCCCCCCCCCCCC | 31.38 | 27251275 | |
146 | Phosphorylation | PRPPQSSTGSTASPP CCCCCCCCCCCCCCC | 40.16 | 26657352 | |
148 | Phosphorylation | PPQSSTGSTASPPVS CCCCCCCCCCCCCCC | 22.38 | 26657352 | |
149 | Phosphorylation | PQSSTGSTASPPVST CCCCCCCCCCCCCCC | 32.28 | 25159151 | |
151 | Phosphorylation | SSTGSTASPPVSTPV CCCCCCCCCCCCCCC | 29.80 | 25849741 | |
155 | Phosphorylation | STASPPVSTPVTGHK CCCCCCCCCCCCCCC | 32.54 | 25627689 | |
156 | Phosphorylation | TASPPVSTPVTGHKR CCCCCCCCCCCCCCC | 23.24 | 25849741 | |
162 | Acetylation | STPVTGHKRMVIPNQ CCCCCCCCCEECCCC | 43.46 | 30590131 | |
173 | Phosphorylation | IPNQPPLTATKKSTL CCCCCCCCCCCCCCC | 37.75 | 28555341 | |
175 | Phosphorylation | NQPPLTATKKSTLKP CCCCCCCCCCCCCCC | 33.50 | 25159151 | |
175 | O-linked_Glycosylation | NQPPLTATKKSTLKP CCCCCCCCCCCCCCC | 33.50 | 30059200 | |
176 | Acetylation | QPPLTATKKSTLKPQ CCCCCCCCCCCCCCC | 42.11 | 26051181 | |
181 | Acetylation | ATKKSTLKPQPAPQA CCCCCCCCCCCCCCC | 41.52 | 26051181 | |
198 | O-linked_Glycosylation | IPVAPIGTLKPQPQP CCEECCCCCCCCCCC | 32.12 | 30059200 | |
200 | Acetylation | VAPIGTLKPQPQPVP EECCCCCCCCCCCCC | 41.25 | 26051181 | |
209 | O-linked_Glycosylation | QPQPVPASYTTASTS CCCCCCCCEECCCCC | 19.55 | 30059200 | |
211 | O-linked_Glycosylation | QPVPASYTTASTSSR CCCCCCEECCCCCCC | 17.25 | 30059200 | |
212 | O-linked_Glycosylation | PVPASYTTASTSSRP CCCCCEECCCCCCCC | 15.46 | 30059200 | |
227 | Phosphorylation | TFNVQVKSAQPSPHY EEEEEEECCCCCCCE | 33.02 | 21945579 | |
231 | Phosphorylation | QVKSAQPSPHYMAAP EEECCCCCCCEEECC | 16.54 | 21945579 | |
234 | Phosphorylation | SAQPSPHYMAAPSSG CCCCCCCEEECCCCC | 7.57 | 21945579 | |
239 | Phosphorylation | PHYMAAPSSGQIYGS CCEEECCCCCCCCCC | 42.23 | 21945579 | |
240 | Phosphorylation | HYMAAPSSGQIYGSG CEEECCCCCCCCCCC | 33.39 | 21945579 | |
244 | Phosphorylation | APSSGQIYGSGPQGY CCCCCCCCCCCCCCC | 9.43 | 21945579 | |
246 | Phosphorylation | SSGQIYGSGPQGYNT CCCCCCCCCCCCCCC | 30.26 | 21945579 | |
251 | Phosphorylation | YGSGPQGYNTQPVPV CCCCCCCCCCCCCCC | 15.13 | 21945579 | |
253 | Phosphorylation | SGPQGYNTQPVPVSG CCCCCCCCCCCCCCC | 26.26 | 21945579 | |
259 | Phosphorylation | NTQPVPVSGQCPPPS CCCCCCCCCCCCCCC | 19.65 | 21945579 | |
266 | Phosphorylation | SGQCPPPSTRGGMDY CCCCCCCCCCCCCCE | 36.19 | 21945579 | |
267 | Phosphorylation | GQCPPPSTRGGMDYA CCCCCCCCCCCCCEE | 38.82 | 21945579 | |
271 | Sulfoxidation | PPSTRGGMDYAYIPP CCCCCCCCCEEECCC | 3.87 | 30846556 | |
273 | Phosphorylation | STRGGMDYAYIPPPG CCCCCCCEEECCCCC | 7.75 | 21945579 | |
275 | Phosphorylation | RGGMDYAYIPPPGLQ CCCCCEEECCCCCCC | 14.02 | 21945579 | |
287 | Phosphorylation | GLQPEPGYGYAPNQG CCCCCCCCCCCCCCC | 20.06 | 21945579 | |
289 | Phosphorylation | QPEPGYGYAPNQGRY CCCCCCCCCCCCCCC | 15.48 | 21945579 | |
296 | Phosphorylation | YAPNQGRYYEGYYAA CCCCCCCCEEEEEEC | 16.82 | 21945579 | |
297 | Phosphorylation | APNQGRYYEGYYAAG CCCCCCCEEEEEECC | 11.08 | 21945579 | |
300 | Phosphorylation | QGRYYEGYYAAGPGY CCCCEEEEEECCCCC | 4.31 | 21945579 | |
301 | Phosphorylation | GRYYEGYYAAGPGYG CCCEEEEEECCCCCC | 10.79 | 21945579 | |
307 | Phosphorylation | YYAAGPGYGGRNDSD EEECCCCCCCCCCCC | 21.38 | 21945579 | |
313 | Phosphorylation | GYGGRNDSDPTYGQQ CCCCCCCCCCCCCCC | 49.38 | 21945579 | |
316 | Phosphorylation | GRNDSDPTYGQQGHP CCCCCCCCCCCCCCC | 45.32 | 21945579 | |
317 | Phosphorylation | RNDSDPTYGQQGHPN CCCCCCCCCCCCCCC | 20.51 | 21945579 | |
325 | Phosphorylation | GQQGHPNTWKREPGY CCCCCCCCCCCCCCC | 36.49 | 21945579 | |
327 | Acetylation | QGHPNTWKREPGYTP CCCCCCCCCCCCCCC | 44.86 | 25953088 | |
327 | Sumoylation | QGHPNTWKREPGYTP CCCCCCCCCCCCCCC | 44.86 | 25114211 | |
327 | Ubiquitination | QGHPNTWKREPGYTP CCCCCCCCCCCCCCC | 44.86 | - | |
332 | Phosphorylation | TWKREPGYTPPGAGN CCCCCCCCCCCCCCC | 27.13 | 21945579 | |
333 | Phosphorylation | WKREPGYTPPGAGNQ CCCCCCCCCCCCCCC | 28.99 | 21945579 | |
345 | Sulfoxidation | GNQNPPGMYPVTGPK CCCCCCCCCCCCCCC | 4.16 | 30846556 | |
346 | Phosphorylation | NQNPPGMYPVTGPKK CCCCCCCCCCCCCCC | 10.64 | 21945579 | |
349 | Phosphorylation | PPGMYPVTGPKKTYI CCCCCCCCCCCCCEE | 43.17 | 21945579 | |
352 | Ubiquitination | MYPVTGPKKTYITDP CCCCCCCCCCEECCC | 60.12 | - | |
352 | Acetylation | MYPVTGPKKTYITDP CCCCCCCCCCEECCC | 60.12 | 26051181 | |
353 | Methylation | YPVTGPKKTYITDPV CCCCCCCCCEECCCC | 50.09 | 115972579 | |
354 | Phosphorylation | PVTGPKKTYITDPVS CCCCCCCCEECCCCC | 26.70 | 28152594 | |
355 | Phosphorylation | VTGPKKTYITDPVSA CCCCCCCEECCCCCC | 15.65 | 28152594 | |
357 | Phosphorylation | GPKKTYITDPVSAPC CCCCCEECCCCCCCC | 24.68 | 28152594 | |
361 | Phosphorylation | TYITDPVSAPCAPPL CEECCCCCCCCCCCC | 31.70 | 28152594 | |
371 | Ubiquitination | CAPPLQPKGGHSGQL CCCCCCCCCCCCCCC | 65.64 | - | |
375 | Phosphorylation | LQPKGGHSGQLGPSS CCCCCCCCCCCCCCC | 31.35 | 25159151 | |
381 | Phosphorylation | HSGQLGPSSVAPSFR CCCCCCCCCCCCCCC | 35.33 | 28555341 | |
382 | Phosphorylation | SGQLGPSSVAPSFRP CCCCCCCCCCCCCCC | 25.98 | 28555341 | |
386 | Phosphorylation | GPSSVAPSFRPEDEL CCCCCCCCCCCHHHH | 24.93 | 27251275 | |
397 | Phosphorylation | EDELEHLTKKMLYDM HHHHHHHHHHHHHCC | 30.44 | 20873877 | |
398 | Ubiquitination | DELEHLTKKMLYDME HHHHHHHHHHHHCCC | 42.41 | - | |
400 | Sulfoxidation | LEHLTKKMLYDMENP HHHHHHHHHHCCCCC | 4.46 | 30846556 | |
402 | Phosphorylation | HLTKKMLYDMENPPA HHHHHHHHCCCCCCH | 15.11 | 28796482 | |
404 | Sulfoxidation | TKKMLYDMENPPADE HHHHHHCCCCCCHHH | 3.20 | 30846556 | |
412 | Phosphorylation | ENPPADEYFGRCARC CCCCHHHHCCCCCCC | 16.33 | 22817900 | |
461 | Ubiquitination | QPFYAVEKKAYCEPC CCEEEEECCEECEEC | 35.78 | - | |
461 | Malonylation | QPFYAVEKKAYCEPC CCEEEEECCEECEEC | 35.78 | 26320211 | |
469 | Phosphorylation | KAYCEPCYINTLEQC CEECEECCCCCHHHC | 14.12 | - | |
504 | Sulfoxidation | PHCFTCVMCHRSLDG CCCEEHHEECCCCCC | 1.41 | 30846556 | |
508 | Phosphorylation | TCVMCHRSLDGIPFT EHHEECCCCCCCCEE | 13.72 | 26657352 | |
537 | Phosphorylation | KKFAPRCSVCKEPIM HHHCCCCCCCCCCCC | 31.65 | 26657352 | |
544 | Sulfoxidation | SVCKEPIMPAPGQEE CCCCCCCCCCCCCCC | 3.20 | 30846556 | |
567 | Phosphorylation | RDFHVHCYRCEDCGG CCEEEEEEECCCCCC | 11.92 | - | |
577 | Phosphorylation | EDCGGLLSEGDNQGC CCCCCCCCCCCCCCC | 44.57 | 27251275 | |
585 | Phosphorylation | EGDNQGCYPLDGHIL CCCCCCCEECCCEEE | 17.41 | 22817900 | |
605 | Phosphorylation | SARIRVLTAKASTDL CCEEEEEEEECCCCC | 24.21 | 22199227 | |
607 | Ubiquitination | RIRVLTAKASTDL-- EEEEEEEECCCCC-- | 37.32 | - | |
609 | Phosphorylation | RVLTAKASTDL---- EEEEEECCCCC---- | 23.03 | 26846344 | |
610 | Phosphorylation | VLTAKASTDL----- EEEEECCCCC----- | 46.29 | 26846344 |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of LPP_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of LPP_HUMAN !! |
Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
---|---|---|---|---|
EGLN2_HUMAN | EGLN2 | physical | 22286099 | |
VHL_HUMAN | VHL | physical | 22286099 | |
PNPO_HUMAN | PNPO | physical | 22939629 | |
AGFG1_HUMAN | AGFG1 | physical | 22863883 | |
HEM2_HUMAN | ALAD | physical | 22863883 | |
ARPC3_HUMAN | ARPC3 | physical | 22863883 | |
ARPC4_HUMAN | ARPC4 | physical | 22863883 | |
CALR_HUMAN | CALR | physical | 22863883 | |
DBNL_HUMAN | DBNL | physical | 22863883 | |
HPBP1_HUMAN | HSPBP1 | physical | 22863883 | |
IPO11_HUMAN | IPO11 | physical | 22863883 | |
P3H1_HUMAN | P3H1 | physical | 22863883 | |
NIF3L_HUMAN | NIF3L1 | physical | 22863883 | |
NPL4_HUMAN | NPLOC4 | physical | 22863883 | |
OGT1_HUMAN | OGT | physical | 22863883 | |
PPME1_HUMAN | PPME1 | physical | 22863883 | |
2A5D_HUMAN | PPP2R5D | physical | 22863883 | |
RAGP1_HUMAN | RANGAP1 | physical | 22863883 | |
RADI_HUMAN | RDX | physical | 22863883 | |
SHLB1_HUMAN | SH3GLB1 | physical | 22863883 | |
TPRKB_HUMAN | TPRKB | physical | 22863883 | |
UBE3A_HUMAN | UBE3A | physical | 22863883 | |
ZPR1_HUMAN | ZPR1 | physical | 22863883 |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Phosphorylation | |
Reference | PubMed |
"Automated phosphoproteome analysis for cultured cancer cells by two-dimensional nanoLC-MS using a calcined titania/C18 biphasic column."; Imami K., Sugiyama N., Kyono Y., Tomita M., Ishihama Y.; Anal. Sci. 24:161-166(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-375 AND THR-397, ANDMASS SPECTROMETRY. | |
"A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-333, AND MASSSPECTROMETRY. | |
"An extensive survey of tyrosine phosphorylation revealing new sitesin human mammary epithelial cells."; Heibeck T.H., Ding S.-J., Opresko L.K., Zhao R., Schepmoes A.A.,Yang F., Tolmachev A.V., Monroe M.E., Camp D.G. II, Smith R.D.,Wiley H.S., Qian W.-J.; J. Proteome Res. 8:3852-3861(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-300 AND TYR-301, ANDMASS SPECTROMETRY. | |
"Global survey of phosphotyrosine signaling identifies oncogenickinases in lung cancer."; Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.; Cell 131:1190-1203(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-317, AND MASSSPECTROMETRY. | |
"Quantitative phosphoproteome analysis using a dendrimer conjugationchemistry and tandem mass spectrometry."; Tao W.A., Wollscheid B., O'Brien R., Eng J.K., Li X.-J.,Bodenmiller B., Watts J.D., Hood L., Aebersold R.; Nat. Methods 2:591-598(2005). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-301 AND TYR-317, ANDMASS SPECTROMETRY. | |
"Immunoaffinity profiling of tyrosine phosphorylation in cancercells."; Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,Zha X.-M., Polakiewicz R.D., Comb M.J.; Nat. Biotechnol. 23:94-101(2005). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-300; TYR-301 ANDTYR-317, AND MASS SPECTROMETRY. | |
"Time-resolved mass spectrometry of tyrosine phosphorylation sites inthe epidermal growth factor receptor signaling network reveals dynamicmodules."; Zhang Y., Wolf-Yadlin A., Ross P.L., Pappin D.J., Rush J.,Lauffenburger D.A., White F.M.; Mol. Cell. Proteomics 4:1240-1250(2005). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-301, AND MASSSPECTROMETRY. | |
"Robust phosphoproteomic profiling of tyrosine phosphorylation sitesfrom human T cells using immobilized metal affinity chromatography andtandem mass spectrometry."; Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,Peters E.C.; Anal. Chem. 76:2763-2772(2004). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-297 AND TYR-300, ANDMASS SPECTROMETRY. | |
"Profiling of tyrosine phosphorylation pathways in human cells usingmass spectrometry."; Salomon A.R., Ficarro S.B., Brill L.M., Brinker A., Phung Q.T.,Ericson C., Sauer K., Brock A., Horn D.M., Schultz P.G., Peters E.C.; Proc. Natl. Acad. Sci. U.S.A. 100:443-448(2003). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-301, AND MASSSPECTROMETRY. |